First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

@article{Johnston2012FirstLineDT,
  title={First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis},
  author={Jessica Johnston and Tsz-Yin So},
  journal={Drugs},
  year={2012},
  volume={72},
  pages={1195-1211}
}
Paediatric multiple sclerosis (MS) is defined as the onset of MS before the age of 18 years. Immunomodulatory disease-modifying therapies (i.e. the interferons [IFNs] and glatiramer acetate) are considered first-line treatments in adult patients with MS, but they are largely understudied in the paediatric population.IFNβ is a type 1 IFN produced by fibroblasts. The therapeutic effect achieved by IFNβ in MS is believed to be the result of a variety of mechanisms, including the inhibition of T… 
The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data
Immunotherapeutic strategies to treat neurodegenerative disorders have inspired the scientific community. The aim of our review is to address the translational aspects of neuroimmunology to describe
Treatment of pediatric multiple sclerosis.
TLDR
Current treatment practices, possible future treatment options, and insight into special problems in the treatment of pediatric patients with MS are summarized.
Multiple Sclerosis: An Update.
TLDR
This article offers a review and update on the disease, focusing on risk factors and possible causes, symptoms, forms of MS, diagnostic criteria and tools, and the expanding array of approved treatments.
Role of the Innate and Adaptive Immune System in the Pathogenesis of PD
TLDR
The potential for translation of immunomodulatory therapies with demonstrated efficacy in preclinical models or other immune-related conditions to the PD clinic is considered, given the implications of the involvement of the immune system on disease progression.
The role of innate and adaptive immunity in Parkinson's disease.
TLDR
The evidence supporting the potential efficacy of immunomodulatory therapies in PD prevention or treatment is reviewed, with a clear need for additional research to clarify the role of immunity and inflammation in this chronic, neurodegenerative disease.
Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic Animal Model of Multiple Sclerosis*
TLDR
This study provides a proof of principle for the application of metabolomics to identify an endogenous metabolite(s) possessing drug-like properties, which is assessed for therapy in preclinical mouse models of MS.
...
1
2
3
...

References

SHOWING 1-10 OF 56 REFERENCES
Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis
TLDR
The safety profile supports the safety and tolerability of interferon beta-1B (IFNβ-1b) in children with multiple sclerosis and related diseases, and all patients treated with IFNβ -1b should undergo regular monitoring of liver function.
Interferon beta-1a in children with multiple sclerosis is well tolerated.
TLDR
Preliminary data indicate that weekly intramuscular injections of IFNB-1 a are well tolerated, and this data indicates that the drug may be well tolerated in children with clinically definite relapsing-remitting multiple sclerosis.
Therapeutic strategies in childhood multiple sclerosis
  • A. Ghezzi
  • Medicine
    Therapeutic advances in neurological disorders
  • 2010
TLDR
Multiple sclerosis in children and adolescents accounts for 3—10% of the whole MS population, and is characterized by a relapsing course in almost all cases, so there is a consensus to treat acute relapses with intravenous high-dose corticosteroids.
Treatment of pediatric multiple sclerosis and variants
TLDR
Current knowledge of DMT in pediatric MS is summarized and experience in several centers treating pediatric MS and MS variants such as neuromyelitis optica or Devic disease, Balo concentric sclerosis, Marburg acute MS, and Schilder disease (myelinoclastic diffuse sclerosis).
Treatment of early-onset multiple sclerosis with intramuscular interferonβ-1a: long-term results
TLDR
IM IFNβ-1a was effective and well tolerated in these paediatric patients with MS and annualised relapse rate decreased to 0.4±0.5.
Mechanisms of Action for Treatments in Multiple Sclerosis
TLDR
The potential mechanisms of action of several effective therapies for MS that are currently available or in development are reviewed and the effects of each treatment are described in terms of their actions on key processes in a five-step model of MS pathogenesis.
Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.
TLDR
Treatment with interferon beta-1a is well tolerated for a long period of time and may be effective in substandard doses in early onset multiple sclerosis.
Randomized, comparative study of interferon β-1a treatment regimens in MS
TLDR
IFNβ-1a 44 μg subcutaneously tiw was more effective than IFNβ -1a 30 μg IM qw on all primary and secondary outcomes investigated after 24 and 48 weeks of treatment.
Interferon-β1a for the treatment of multiple sclerosis
TLDR
O Ongoing trials with new powerful immunomodulatory drugs, such as monoclonal antibodies, that require only monthly or bimonthly parenteral administrations will probably offer a better tolerated treatment option in the near future.
Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study
The ITEM study group was organised in Italy to evaluate the effectiveness and safety of interferon-beta (IFNβ) and glatiramer acetate (GA) in multiple sclerosis (MS) patients treated before 16 years
...
1
2
3
4
5
...